Pancreatic Cancer Research

ResearcherSouthwest UniversityActive in the last 2 years

Hongjuan Cui

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1178-1570; OpenAlex author ID A5046447304. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
6
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 4

  1. Moracin D suppresses cell growth and induces apoptosis via targeting the XIAP/PARP1 axis in pancreatic cancer. Last author DOI 10.1016/j.phymed.2024.155527↗
  2. Antibiotic tigecycline inhibits cell proliferation, migration and invasion via down-regulating CCNE2 in pancreatic ductal adenocarcinoma. Last author DOI 10.1111/jcmm.15086↗
  3. Silencing ubiquitin-conjugating enzyme 2C inhibits proliferation and epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/febs.15134↗
  4. Pathological and prognostic role of mdig in pancreatic cancer. Co-author DOI 10.18632/genesandcancer.149↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xi Zoë Zhong · 1 shared paper, 2024 · strength 0.22
  2. Jie Yang · 1 shared paper, 2020 · strength 0.12
  3. Xianxing Wang · 1 shared paper, 2019 · strength 0.10
  4. Huaizhi Wang · 1 shared paper, 2019 · strength 0.10
  5. Srinivas Kumar · 1 shared paper, 2017 · strength 0.09
  6. Fei Chen · 1 shared paper, 2017 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.